Results 211 to 220 of about 30,845,260 (288)

GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review. [PDF]

Nutrients
Myśliwczyk D, Gofron KK, Wasilewski A, Myśliwiec M, Wasilewska E.   +4 more
europepmc   +1 more source

The Cautious Promise of GLP-1 Receptor Agonists

Ochsner Journal
openaire   +2 more sources

Positive modulation of glucagon‐like peptide 1 (GLP‐1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes

British Journal of Pharmacology, EarlyView.
Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan, Rwdah Mohamed Alameri, Yasir S. Raouf, Damien Maurel, Naiem Ahmad Wani, Anatoliy Shmygol, Irfa Anwar, Heng B. See, Elizabeth K. M. Johnstone, Elodie Dupuis, Eric Trinquet, Kevin D. G. Pfleger, Emilia Oueis, Mohammed Akli Ayoub   +13 more
wiley   +1 more source

Genetic Insights Into Protective Effects of GLP-1 Receptor Agonists on Stroke and Alzheimer Disease Across Ancestries. [PDF]

Neurol Genet
Caro-Châtelier I, Sargurupremraj M, Yang C, Akinleye C, Trégouët DA, Akinyemi RO, Shigemizu D, Coker M, Akinyemi JO, Tiwari HK, Chasman DI, Ovbiagele B, Chabriat H, Mooser V, Couffinhal T, Mishra A, Cruchaga C, Reitz C, Kunkle B, Kamatani Y, Owolabi MO, Mohammedi K, Debette S.   +22 more
europepmc   +1 more source

The dual incretin agonist tirzepatide blunts nicotine‐induced behaviours and neurochemistry in male mice

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Nicotine dependence remains one of the leading causes of morbidity and mortality worldwide, with high relapse rates and post‐cessation weight gain representing persistent barriers to sustained abstinence. The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have ...
Christian E. Edvardsson, Thaynnam A. Emous, Sarah Witley, Mia Ericson, Louise Adermark, Elisabet Jerlhag   +5 more
wiley   +1 more source

Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Khademi R, Shoar S.
europepmc   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

Clinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams, Bonnie Grant, Richard Quinton, Channa N. Jayasena   +3 more
wiley   +1 more source

GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials. [PDF]

J Neuroendocrinol
Gupta P, Pozzilli V, De Giovanni A, Sapio E, Motolese F, Capone F, Pozzilli P.   +6 more
europepmc   +1 more source

Liver Organoids: From Disease Modelling to Regenerative Medicine

Cell Proliferation, EarlyView.
Liver organoids provide a versatile platform for disease modelling and drug discovery, leveraging stem cells and engineering techniques. They bridge research and clinical applications, offering significant potential for advancing precision medicine and regenerative therapies for liver diseases.
Tiepeng Wang, Xiaotian Qu, Jinhong Si, Junkang Meng, Ting Zhang, Shuliang Niu   +5 more
wiley   +1 more source